Newsroom

September 16, 2021
VALEO PHARMA TO REPORT THIRD QUARTER 2021 RESULTS AND HOLD INVESTORS CONFERENCE CALL / WEBCAST
August 16, 2021
VALEO PHARMA REPORTS ON LAUNCH OF NEW CORPORATE STRUCTURE
July 13, 2021
VALEO PHARMA ANNOUNCES ADDITIONAL PROVINCIAL REIMBURSEMENT COVERAGE FOR REDESCA™ AND REDESCA HP™
June 29, 2021
VALEO PHARMA REPORTS ITS SECOND QUARTER 2021 RESULTS AND HIGHLIGHTS
June 29, 2021
VALEO PHARMA CLOSES $11.5 MILLION BOUGHT-DEAL PUBLIC OFFERING, INCLUDING FULL EXERCISE OF THE OVER-ALLOTMENT OPTION
June 23, 2021
VALEO PHARMA TO REPORT SECOND QUARTER 2021 RESULTS AND HOLD INVESTORS CONFERENCE CALL / WEBCAST
June 22, 2021
VALEO PHARMA ANNOUNCES COMMERCIAL LAUNCH OF ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®
June 8, 2021
VALEO PHARMA ANNOUNCES $10.0 MILLION BOUGHT-DEAL PUBLIC OFFERING OF UNITS
June 1, 2021
VALEO PHARMA PROVIDES UPDATE ON PRIVATE PAYER REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®
May 26, 2021
VALEO PHARMA PROJECTING RECORD REVENUES FOR SECOND QUARTER 2021
May 17, 2021
VALEO PHARMA JOINS INNOVATIVE MEDICINES CANADA
April 29, 2021
VALEO PHARMA ANNOUNCES VOTING RESULTS OF ITS 2021 ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
April 28, 2021
VALEO PHARMA’S REDESCA® AND REDESCA HP® TO BE COVERED UNDER THE ONTARIO PUBLIC DRUG BENEFIT PROGRAM
April 27, 2021
VALEO PHARMA UPSIZES AND CLOSES $6.6 MILLION NON-BROKERED PRIVATE PLACEMENT
April 15, 2021
VALEO PHARMA ANNOUNCES COMMERCIAL LAUNCH OF REDESCA™ AND REDESCA HP™
April 14, 2021
VALEO PHARMA ANNOUNCES $4.0 MILLION NON-BROKERED PRIVATE PLACEMENT OF NON-CONVERTIBLE DEBENTURES
April 6, 2021
VALEO PHARMA COMPLETES NEGOTIATIONS WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR REDESCA® AND REDESCA HP®
March 31, 2021
VALEO PHARMA REPORTS ITS FIRST QUARTER 2021 RESULTS AND HIGHLIGHTS
March 29, 2021
VALEO PHARMA INC. ENTERS INTO AN AGREEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN CANADA
March 26, 2021
VALEO PHARMA TO REPORT FIRST QUARTER 2021 RESULTS AND HOLD INVESTORS CONFERENCE CALL / WEBCAST
February 24, 2021
VALEO PHARMA REPORTS ITS 2020 FOURTH QUARTER AND YEAR-END RESULTS AND HIGHLIGHTS
February 19, 2021
VALEO PHARMA TO REPORT FOURTH QUARTER AND 2020 YEAR-END RESULTS AND HOLD INVESTORS CONFERENCE CALL / WEBCAST
February 17, 2021
VALEO PHARMA’S HESPERCO™ CAPSULES AT THE CORE OF MONTREAL HEART INSTITUTE’S HESPERIDIN CORONAVIRUS CLINICAL TRIAL
January 25, 2021
VALEO PHARMA’S REDESCA™ RECEIVES POSITIVE RECOMMENDATION FOR PUBLIC REIMBURSEMENT IN QUEBEC
January 18, 2021
VALEO PHARMA ANNOUNCES MAJOR ADDITION TO ITS SENIOR MANAGEMENT TEAM
January 12, 2021
VALEO PHARMA HIGHLIGHTS MDBRIEFCASE NEWSLETTER COMPARING HESPERIDIN AND VITAMIN C FOR COVID-19
December 29, 2020
VALEO PHARMA ANNOUNCES DTC ELIGIBILITY FOR THE TRADING OF ITS SHARES ON THE US OTCQB MARKET
December 9, 2020
VALEO PHARMA ANNOUNCES HEALTH CANADA APPROVAL FOR REDESCA™ AND REDESCA HP™
November 12, 2020
VALEO PHARMA ANNOUNCES AMIKACIN APPROVAL IN CANADA AND U.S. LAUNCH OF ETHACRYNATE SODIUM
October 13, 2020
VALEO PHARMA ANNOUNCES THAT HESPERCO™ HAS STARTED SHIPPING
September 29, 2020
VALEO PHARMA REPORTS ITS THIRD QUARTER 2020 RESULTS AND HIGHLIGHTS
September 23, 2020
VALEO PHARMA BEGINS TRADING ON THE U.S. OTCQB MARKET
September 23, 2020
VALEO PHARMA TO REPORT THIRD QUARTER 2020 RESULTS AND HOLD INVESTORS CONFERENCE CALL / WEBCAST
September 11, 2020
VALEO PHARMA WARRANTS TO BEGIN TRADING TODAY ON CSE UNDER THE SYMBOL VPH.WT.A
September 10, 2020
VALEO PHARMA ANNOUNCES CLOSING OF BOUGHT DEAL FINANCING INCLUDING EXERCISE OF OVER-ALLOTMENT OPTION FOR GROSS PROCEEDS OF $6.9 MILLION
September 3, 2020
VALEO PHARMA RECEIVES HESPERCO NATURAL PRODUCT LICENSE APPROVAL FROM HEALTH CANADA
August 24, 2020
VALEO PHARMA HAS SUBMITTED HESPERCO NATURAL PRODUCT LICENSE APPLICATION FOR APPROVAL TO HEALTH CANADA
August 20, 2020
VALEO PHARMA ANNOUNCES $6.0 MILLION BOUGHT DEAL FINANCING
August 12, 2020
VALEO PHARMA COMMENCES YONDELIS® COMMERCIALIZATION IN CANADA
August 5, 2020
VALEO PHARMA NOTIFIES WARRANTS HOLDERS OF UNCHANGED EXPIRY DATE
July 29, 2020
VALEO PHARMA APPLIES FOR LISTING ON THE U.S. OTCQB MARKET
July 28, 2020
VALEO PHARMA TO PRESENT AT WALL STREET REPORTER’S LIVESTREAM CONFERENCE ON JULY 29, 2020
July 13, 2020
VALEO PHARMA RECEIVES APPROVAL FROM HEALTH CANADA FOR THE TRANSFER OF COMMERCIAL RIGHTS TO AMETOP
July 10, 2020
VALEO PHARMA CLOSES $1.7 MILLION OVERSUBSCRIBED PRIVATE PLACEMENT
July 2, 2020
VALEO PHARMA REPORTS ITS 2020 SECOND QUARTER RESULTS AND INITIATES $1 MILLION DEBENTURE PRIVATE PLACEMENT
June 16, 2020
VALEO PHARMA RECEIVES FDA APPROVAL FOR ETHACRYNATE SODIUM
June 8, 2020
VALEO PHARMA RECEIVES APPROVAL FROM HEALTH CANADA FOR THE TRANSFER OF COMMERCIAL RIGHTS TO YONDELIS® IN CANADA
April 28, 2020
VALEO PHARMA LICENSES CANADIAN RIGHTS TO AMETOP GEL FROM ALLIANCE PHARMA
March 27, 2020
VALEO PHARMA REPORTS ITS 2020 FIRST QUARTER RESULTS
March 17, 2020
VALEO PHARMA COMMENTS ON WORLD HEALTH ORGANIZATION’S BEST PRACTICES RECOMMENDING USE OF LOW MOLECULAR WEIGHT HEPARIN TO HELP PREVENT COMPLICATIONS RELATED TO COVID-19 INFECTIONS
February 28, 2020
VALEO PHARMA REPORTS 2019 FINANCIAL RESULTS AND CLOSING OF $2.1 MILLION PRIVATE PLACEMENT
February 6, 2020
VALEO PHARMA’S ONSTRYV RECEIVES POSITIVE RECOMMENDATION FOR PUBLIC REIMBURSEMENT IN QUEBEC
January 21, 2020
VALEO PHARMA SIGNS LICENSING AGREEMENT WITH PHARMAMAR TO COMMERCIALIZE YONDELIS® IN CANADA

2019